Regulatory Approval of Rubicon's ANDA220869 Alters Cough and Cold Market Dynamics
Respiratory · Cough and Cold • Regulatory Approval • Jul 7, 2026
Assessment confidence: 71% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
Executive Thesis
The FDA's approval of Rubicon Research's ANDA220869 for Promethazine and Dextromethorphan positions the company favorably within the competitive cough and cold market. This development necessitates close monitoring of market dynamics and competitor strategies as Rubicon prepares for market entry. Regulatory context from FDA (FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)) supports the near-term read. Assessment grounded in 12 ranked evidence items (8 high-relevance).
Strategic Assessment
Portfolio teams should assess the competitive landscape for cough and cold products and consider strategic positioning for Rubicon's offering. The strongest clinical anchor is vNOTES vs Laparoscopy: Respiratory Mechanics and Hemodynamics (ClinicalTrials.gov), weak alignment to signal sub-indication and entities. In rare disease, 8 regulatory and 4 competitive items passed relevance filtering for competitors with similar formulations.
Competitive Pressure
The most relevant competitive pressure comes from [Ad hoc announcement pursuant to Art. (Roche) — sponsor/company relevance (roche). Secondary pressure from Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217). This approval status may enhance Rubicon Research's position in the cough and cold market, potentially impacting competitors with similar formulations.
Regulatory Outlook
Regulatory risk is concentrated around FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG) (FDA). Sub-indication match (rare disease); Regulatory pathway relevance (nda).
Key Risks
- Elevated medium regulatory exposure for competitors with similar formulations could delay market entry or constrain labeling if agency review intensifies.
Key Opportunities
- Rubicon's entry into the market with this combination product could disrupt existing market shares and influence pricing strategies among competitors, potentially affecting overall revenue in the cough and cold segment.
- Portfolio teams should assess the competitive landscape for cough and cold products and consider strategic positioning for Rubicon's offering.
What Would Change This Assessment
- This becomes more urgent if Monitor the final approval and market entry timeline for ANDA220869, as well as competitor responses.
- Timeline shift beyond mid term would change urgency.
- A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.
Supporting Evidence
FDA AP — PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE (ORIG)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE (ORIG)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — DEXTROMETHORPHAN POLISTIREX (ORIG)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — DEXTROMETHORPHAN POLISTIREX (ORIG)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — BUTORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — LEVORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — BUTORPHANOL TARTRATE (SUPPL)
FDAhigh relevance
Sub-indication match (rare disease); Regulatory pathway relevance (nda)
FDA document
View source
vNOTES vs Laparoscopy: Respiratory Mechanics and Hemodynamics
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceRSV Immunisation Status in Queensland (Australia)
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceEndocarditis Clinical Awareness, Research, and Evaluation in Sweden
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceA Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceEffect of Feeding Status on Appetite and Eating Behaviour.
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceThe Effect of Changes in the Frequency of Endotracheal Tube Repositioning in Intensive Care Units on the Prevention of Oral Mucosal Pressure Injuries
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceENDO1000 - A UK-wide Endometriosis Research Project
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceEffect of AI-Assisted Respiratory Training on Pain, Fatigue and Respiratory Parameters in Patients After Open Heart Surgery
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
[Ad hoc announcement pursuant to Art.
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View sourceRoche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochemedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
Immunotherapeutic landscape of amyotrophic lateral sclerosis: A bibliometric analysis of research trends, translational priorities, and collaboration networks (2006-2025).
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceNeoadjuvant immunochemotherapy and postoperative acute hypoxemic respiratory failure in thoracic surgery: a multicentre cohort study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceClinical research progress and challenges of vaccine for human papillomavirus-associated cancers.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceAdvances in SEC61G research: from ER translocon subunit to emerging pan-cancer oncogenic roles.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View sourceResearch progress of ferroptosis in gynecological diseases.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Related Signals
Related Regulatory Precedents
FDA
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
Application ANDA074278. Sponsor: HIKMA. Submission status: AP. Submission type: SUPPL. Active ingredients: LEVORPHANOL TARTRATE.
SourceFDA
FDA AP — BUTORPHANOL TARTRATE (SUPPL)
Application ANDA075499. Sponsor: APOTEX. Submission status: AP. Submission type: SUPPL. Active ingredients: BUTORPHANOL TARTRATE.
SourceFDA
FDA AP — LEVORPHANOL TARTRATE (SUPPL)
Application ANDA211484. Sponsor: ACERTIS PHARMS. Submission status: AP. Submission type: SUPPL. Active ingredients: LEVORPHANOL TARTRATE.
SourceFDA
FDA AP — BUTORPHANOL TARTRATE (SUPPL)
Application ANDA075824. Sponsor: HIKMA. Submission status: AP. Submission type: SUPPL. Active ingredients: BUTORPHANOL TARTRATE.
SourceFDA
FDA AP — DEXTROMETHORPHAN POLISTIREX (ORIG)
Application ANDA218417. Sponsor: AUROBINDO PHARMA LTD. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: DEXTROMETHORPHAN POLISTIREX.
Source